Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dexter Yan

Senior Reporter

Shanghai, China

Dexter Yan is a senior writer covering China’s surging pharma industry on the APAC Pharma news team. With a keen interest in R&D and commercial activities taking place around the clock, he is always on the lookout for opportunities to keep readers better informed of any developments in the field.

Latest From Dexter Yan

ASCO Preview: Multiple Chinese Biotechs Showcase NSCLC Assets

Chinese biotechs Biokin, Dizal, Junshi and Kelun Biotech are presenting four of the most closely-followed oral reports at ASCO on new clinical results for their candidates for non-small cell lung cancer.

China Clinical Trials

Chinese Public Payer Data Show More New Drugs Get Faster Coverage

China’s Basic Medical Insurance Fund spent 7.1 times more on novel drugs in 2022 compared to 2019, according to figures disclosed by the National Healthcare Security Administration. Meanwhile, such drugs need to wait less to be eligible for reimbursement in China.

China Reimbursement

Chinese Language Podcast: 重磅交易, 亚太药企如何度过资本寒冬, 减肥药风口

The latest China biopharma trends, including recent multimillion dollar deals by biotech firms, companies preparing for the worst as the 'capital winter' lingers, and GLP-1 agents for obesity are discussed by Brian Yang in Beijing and Dexter Yan in Shanghai in this latest Chinese-language podcast.

China Deals

Mazdutide Consolidates Potential Efficacy Lead In China GLP-1 Obesity Race

Higher-dose mazdutide showed superiority over placebo after 24 weeks of treatment in a Phase II trial in Chinese adults with obesity. The potential best-in-class efficacy profile of the Lilly-originated GLP-1 receptor agonist is expected to help it gain the upper hand in the race for the leadership of the country's obesity market, estimated at $5.5bn in 2030.

Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate

In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos.

Deal Watch Deals

China Biotech Finance Watch: Luzhu Bags $43.5m In Hong Kong IPO

In the private market, eight Chinese biotechs raised a combined $116m in deals backed by venture capital and private equity firms over the past few weeks.

China Financing
See All
UsernamePublicRestriction

Register